

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/214038 A1

(51) International Patent Classification:

C07D 207/16 (2006.01) C07D 403/12 (2006.01)
C07D 209/52 (2006.01) A61P 3/10 (2006.01)
C07D 401/12 (2006.01) A61K 31/4025 (2006.01)
C07D 401/14 (2006.01)

(21) International Application Number:

PCT/IB2024/053554

(22) International Filing Date:

11 April 2024 (11.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/496,232 14 April 2023 (14.04.2023) US
63/598,698 14 November 2023 (14.11.2023) US

(71) Applicant: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **FILIPSKI, Kevin James**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **FISHER, Ethan Lawrence**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **GUAN, Yanfei**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **LEVI, Samuel Michael**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **LI, Qifang**; 173 Dawley Drive, Stonington, Connecticut 06378 (US). **MARTINEZ ALSINA, Luis Angel**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **O'NEIL, Steven Victor**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **PANCHAGNULA, Advaita**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US).


RANKIC, Danica Antonia; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **REESE, Matthew Richard**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **SAMMONS, Matthew Forrest**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **WANG, Yang**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **ZHANG, Lei**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., Legal Division, 66 Hudson Boulevard East, 11th Floor, New York, New York 10001-2192 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF



(57) Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R^1 , R^2 , R^3 , L^1 , T^1 , T^2 , T^3 , T^4 , $t1$, and $t2$ are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.

WO 2024/214038 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*